-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is from NEJM Journal Watch Distinct Signatures of Lung Cancer Types in Never-Smokers.
Comments on the unique labeling of lung cancer types in Never-Smokers Author: Jyoti D.
Patel, MD, FASCO Tumors in Never-Smokers The genomic characteristics of the tumor are very different from those of smokers
.
Never smokers account for 10% to 25% of all lung cancer patients, and almost all suffer from lung adenocarcinoma
.
At present, several studies have classified the genomic characteristics of lung cancer in smokers, and this study is the first study to evaluate lung cancer in a large number of non-smokers
.
Researchers at the National Cancer Institute in the United States have sequenced the whole genome of 232 lung cancers from never-smokers
.
They found three subtypes defined by changes in somatic cell copy number.
These subtypes are very different from smokers' lung adenocarcinoma
.
They named these subtypes "piano" (weak), "mezzo-forte" (medium strong) and "forte" (strong) using musical terms that express differences in loudness
.
The "piano" subtype accounts for nearly half of all samples, including carcinoid tumors; these tumors have low mutation burden, long telomeres, and slow growth
.
Mutations in the driver gene of the "piano" subtype suggest stem cell-like characteristics
.
About 1/3 of tumors are of the "mezzo-forte" subtype, and nearly half of them have specific chromosome arm level mutations or EGFR mutations, and have a short incubation period
.
The most aggressive tumors are the "forte" subtype; these tumors are dominated by whole-genome doubling mutations, have short telomeres and have aggressive behavior, and are most similar to smokers' lung cancer
.
Commenting on this research gives us a deeper understanding of lung cancer in never-smokers
.
These results may help improve the choice of treatment options (for example, avoiding first-line immunotherapy for some patients and avoiding adjuvant chemotherapy for others), and ultimately improve the prevention and screening of high-risk patients
.
Commented article Zhang T et al.
Genomic and evolutionary classification of lung cancer in never smokers.
Nat Genet 2021 Sep; 53:1348.
(https://doi.
org/10.
1038/s41588-021-00920-0) NEJM journal collection NEJM Journal Watch is published by NEJM Group.
Internationally renowned doctors are invited to comment on important papers in the medical field to help doctors understand and use the latest developments
.
"NEJM Frontiers of Medicine" is translated several times a week, published on the app and official website, and selected 2-3 articles are published on WeChat
.
Copyright information This article was translated, written or commissioned by the "NEJM Frontiers of Medicine" jointly created by the Jiahui Medical Research and Education Group (J-Med) and the "New England Journal of Medicine" (NEJM)
.
The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group
.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities
.
Comments on the unique labeling of lung cancer types in Never-Smokers Author: Jyoti D.
Patel, MD, FASCO Tumors in Never-Smokers The genomic characteristics of the tumor are very different from those of smokers
.
Never smokers account for 10% to 25% of all lung cancer patients, and almost all suffer from lung adenocarcinoma
.
At present, several studies have classified the genomic characteristics of lung cancer in smokers, and this study is the first study to evaluate lung cancer in a large number of non-smokers
.
Researchers at the National Cancer Institute in the United States have sequenced the whole genome of 232 lung cancers from never-smokers
.
They found three subtypes defined by changes in somatic cell copy number.
These subtypes are very different from smokers' lung adenocarcinoma
.
They named these subtypes "piano" (weak), "mezzo-forte" (medium strong) and "forte" (strong) using musical terms that express differences in loudness
.
The "piano" subtype accounts for nearly half of all samples, including carcinoid tumors; these tumors have low mutation burden, long telomeres, and slow growth
.
Mutations in the driver gene of the "piano" subtype suggest stem cell-like characteristics
.
About 1/3 of tumors are of the "mezzo-forte" subtype, and nearly half of them have specific chromosome arm level mutations or EGFR mutations, and have a short incubation period
.
The most aggressive tumors are the "forte" subtype; these tumors are dominated by whole-genome doubling mutations, have short telomeres and have aggressive behavior, and are most similar to smokers' lung cancer
.
Commenting on this research gives us a deeper understanding of lung cancer in never-smokers
.
These results may help improve the choice of treatment options (for example, avoiding first-line immunotherapy for some patients and avoiding adjuvant chemotherapy for others), and ultimately improve the prevention and screening of high-risk patients
.
Commented article Zhang T et al.
Genomic and evolutionary classification of lung cancer in never smokers.
Nat Genet 2021 Sep; 53:1348.
(https://doi.
org/10.
1038/s41588-021-00920-0) NEJM journal collection NEJM Journal Watch is published by NEJM Group.
Internationally renowned doctors are invited to comment on important papers in the medical field to help doctors understand and use the latest developments
.
"NEJM Frontiers of Medicine" is translated several times a week, published on the app and official website, and selected 2-3 articles are published on WeChat
.
Copyright information This article was translated, written or commissioned by the "NEJM Frontiers of Medicine" jointly created by the Jiahui Medical Research and Education Group (J-Med) and the "New England Journal of Medicine" (NEJM)
.
The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group
.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities
.
